Effect of sodium glucose cotransporter 2 inhibitors on cardiac function and cardiovascular outcome: a systematic review
Keyword(s):
Abstract A high incidence of left ventricular diastolic dysfunction and increased risk of cardiovascular events have been reported in patients with diabetes mellitus. Sodium glucose cotransporter 2 (SGLT2) inhibitors selectively inhibit kidney glucose and sodium reabsorption, and cardiovascular benefits of SGLT2 inhibitors beyond other antidiabetic drugs have been reported in type 2 diabetes mellitus (T2DM) clinical trials. However, underlying mechanisms contributing to the improvement of cardiovascular outcomes have not been clearly identified. In this review, likely mechanisms of SGLT2 inhibitors contributing to a favorable cardiovascular outcomes are discussed based on experimental and clinical studies on cardiac function.
2020 ◽
Vol 40
(3)
◽
pp. 506-522
◽
2019 ◽
Vol 15
(4)
◽
pp. 259-262
◽
2020 ◽
2005 ◽
Vol 26
(S 1)
◽
Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction
2019 ◽
Vol 19
(20)
◽
pp. 1818-1849
◽
Keyword(s):
2018 ◽
Vol 39
(2)
◽
pp. 179-186
◽